Overview A Clinical Study of TQH3821 Tablets in the Treatment of Treated Rheumatoid Arthritis Status: Not yet recruiting Trial end date: 2024-12-01 Target enrollment: Participant gender: Summary To evaluate the efficacy and safety of TQH3821 in treated patients with moderate-to-severe active rheumatoid arthritis. Phase: Phase 2 Details Lead Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.